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Abstract
Background: In head trauma cases involving antiplatelet agent treatment, the French Society of Emergency
Medicine recommends performing computed tomography (CT) scans to detect brain lesions, 90% of which are
normal. The value of CT is still debatable given the scarce number of studies and controversial results.
Methods: We used the RATED registry (Registry of patient with Antithrombotic agents admitted to an Emergency
Department, NCT02706080) to assess factors of cerebral bleeding related to antiplatelet agents following head
trauma.
Results: From January 2014 to December 2015, 993 patients receiving antiplatelet agents were recruited, 293 (29.5%)
of whom underwent CT scans for brain trauma. Intracranial bleeding was found in 26 (8.9%). Multivariate analysis
revealed these patients more likely to have a history of severe hemorrhage (odds ratio [OR]: 8.47, 95% confidence
interval [CI]: 1.56–45.82), dual antiplatelet therapy (OR: 6.46, 95%CI:1.46–28.44), headache or vomiting (OR: 4.27, 95%CI:
1.44–2.60), and abnormal Glasgow coma scale (OR: 8.60; 95%CI: 2.85–25.99) compared to those without intracranial
bleeding. The predictive model derived from these variables achieved 98.9% specificity and a negative predictive value
of 92%. The area under the ROC curve (AUROC) was 0.85 (95%CI: 0.77–0.93).
Conclusions: Our study demonstrated that the absence of history of severe hemorrhage, dual antiplatelet therapy,
headache or vomiting, and abnormal Glasgow coma scale score appears to predict normal CT scan following traumatic
brain injury in patients taking antiplatelets. This finding requires confirmation by prospective studies.
Trial registration: ClinicalTrials.gov number: NCT02706080.
Background
Traumatic brain injury (TBI) is very common in emer-
gency departments (EDs), with an annual incidence of
approximately 150 to 300 per 100,000 persons in
Europe, and one million per year in the USA [1–3].
Most (95%) are caused by mild head injury defined by a
Glasgow coma scale score ≥ 13 [4, 5]. Moreover, TBI is a
common cause of death and disability, most often in
young people but increasingly among the elderly [6].
Patients over 65 years old represent 25% of all
trauma-related deaths [7]. Falls are particularly the lead-
ing cause of death by trauma [8].
This population is especially cause for concern due to
their increased use of antiplatelets. Some studies re-
ported no correlation between acetylsalicylic acid (ASA)
administration and the incidence of post-traumatic
intracranial lesions [9, 10]. Others, however, have found
a link between antiplatelet agents and intracranial
hemorrhage or mortality [11–15]. Particularly, clopido-
grel appears to be associated with an increased risk of
morbidity [16, 17]. Recently, a meta-analysis revealed a
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correlation between antiplatelet therapy and post-traumatic
cerebral hemorrhage (odds ratio [OR]: 1.87; 95% confidence
interval [CI]: 1.27–2.74) [18].
Clinical prediction rules based on prospective studies
can identify which head trauma patients are at low risk
of intracerebral hemorrhage (ICH) or neurosurgical le-
sions [19, 20]. However, these studies excluded patients
receiving antiplatelet agents. The French guidelines thus
prioritize CT as the gold standard for head trauma de-
tection during antiplatelet agent administration [21]. For
the other guidelines, however, antiplatelet agents are not
listed as ICH risk factors [22, 23]. Some authors have
attempted to define predictive factors for cerebral bleed-
ing, like the Glasgow coma scale, loss of consciousness,
headache or vomiting, yet most included patients taking
anticoagulants or antiplatelets [14, 15, 24].
Choosing the optimum way to assess head trauma in
antiplatelet agent cases is a significant challenge facing
emergency physicians. Given the small number of stud-
ies producing controversial findings, a specific study on
the bleeding risk factors for these particular patients
with head trauma appears crucial in order to avoid un-
necessary CT scanning. Our study sought to assess the
factors related to traumatic intracranial bleeding in pa-
tients taking antiplatelet agents admitted to our ED.
Methods
Inclusion criteria
Consecutive patients admitted to the ED of a university
hospital and receiving antithrombotic treatment at the
time of admission were logged in the RATED registry
(Registry of patient with Antithrombotic agents admitted
to an Emergency Department, NCT02706080). All pa-
tients (or their legal power of attorney) were informed of
the potential use of their personal data and none op-
posed consent. This analysis was approved by the appro-
priate regional French research ethics committee (CPP
Sud-Est VI, IRB number: 00008526–2013/CE37).
RATED is a monocentric, ongoing (from January
2014), observational registry of consecutive patients tak-
ing antithrombotic drugs, admitted to our University
Hospital ED for any reason. As far as they were able, the
emergency physicians enrolled consecutive patients dur-
ing each patient’s medical management. Thus, data was
recorded in a digital case report form in the hospital pa-
tient records.
Study design
We conducted a monocentric, retrospective study that
used prospectively-collected data from consecutive pa-
tients enrolled in the RATED registry from January 2014
to December 2015. For this study, to follow the French
Society recommendations, all patients receiving anti-
platelet drugs on admission, and presenting with head
traumas received a CT scan within 4 to 8 h and were in-
cluded [21]. Those under anticoagulants were excluded.
This study sought to assess the clinical predictive fac-
tors for intracranial bleeding in patients who underwent
TBI while taking antiplatelets.
Baseline variables
The following parameters are routinely recorded in
RATED: patient’s baseline characteristics; clinical status
including any coexisting or underlying conditions; bleed-
ing risk factors described in the literature (age, previous
stroke, previous gastrointestinal bleeding, renal impair-
ment, anemia, thrombocytopenia, liver disease, cancer,
hypertension, dementia, alcohol) [25–28], and the use of
antiplatelet therapy; use of CT scan or ultrasound; la-
boratory data at baseline; the antithrombotic treatment
(indication, time duration, drugs, doses); concomitant
drugs; death during hospitalization. For this study, we
focused on the intracranial bleeding predictive factors
that are already known: age, history of major bleeding
(history of bleeding leading to transfusion, bleeding in a
critical area and bleeding leading to hemodynamic in-
stability by taking into account the patient history during
the different hospital stay), anemia (defined as a
hemoglobin count < 12 g/dl in women and < 13 in men),
thrombocytopenia (defined as a platelet count < 150 G/
l), renal failure, alcohol intake, neurological examination,
Glasgow coma scale, headache or vomiting, loss of con-
sciousness, and amnesia [14, 21, 24, 25]. Radiological se-
verity was evaluated by calculating the Rotterdam CT
score on the first scan performed in the emergency
room as follows: (a) status of basal cisterns subdivided
into normal (0), compressed (1), or absent (2); (b) mid-
line shift subdivided into 0-5 mm (0) or > 5 mm (1); (c)
epidural hematoma subdivided into present (0) or absent
(1); (d) traumatic subarachnoid hemorrhage or intraven-
tricular hemorrhage subdivided into absent (0) or
present (1) [29, 30]. According to the CT scan results,
we then compared patients with intracranial bleeding
(CT group+) to those without (CT group-).
Statistical analysis
It was difficult to estimate a sample size based on the lit-
erature in order to identify predictive factors for intracra-
nial bleeding in patients taking antiplatelets presenting
with head trauma. While numerous rules-of-thumb have
previously been suggested for determining the minimum
number of subjects required for conducting multiple re-
gression analyses, these are heterogeneous and often have
minimal empirical evidence. For multiple regression
models, some authors suggest variable ratios of 15:1 or
30:1 when generalization is critical [31–34]. Considering
these works and the intracranial bleeding rate, we deemed
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a sample size of approximately 300 subjects relevant to
obtain satisfactory statistical power.
All statistical analyzes were performed with Stata soft-
ware (Version 13, StataCorp, College Station, US) for a
two-sided error significance level of 5%. Continuous data
was presented as mean ± standard deviation or median
[interquartile range], according to statistical distribution
(Shapiro-Wilk test for normality). Comparisons between
groups (CT group- and CT group+) were performed
using classic statistical tests: Student’s t-test or the non-
parametric Mann-Whitney test if the t-test assumptions
were not met ([i] normality and [ii] homoscedasticity,
analyzed by Fisher-Snedecor). For the categorical param-
eters, groups were compared using Chi-squared test or
Fisher’s exact test. Multivariable logistic regression ana-
lysis was then performed considering covariates deter-
mined according to univariate results (p < 0.20) [35] and
clinical relevance (following the literature) like age, gen-
der, and loss of consciousness. A particular attention has
been paid to the study of multicollinearity and interac-
tions between covariates 1) studying the relationships
between the covariables and 2) evaluating the impact to
add or delete variables on multivariable model. The se-
lection model was carried out by backward stepwise
strategy based on Akaike information criteria. Then, the
final model was validated by a two-step bootstrapping
process. For each step, bootstrap samples with replace-
ments (n = 1000) were generated from the training set.
In the first phase, the percentage of models including
each initial variable was determined by the classic step-
wise approach. Then, in the second phase, the parame-
ters of generalized linear regression (logistic for
dichotomous dependent variables) of the final model
were independently estimated. Finally, the bootstrap esti-
mates associated with each covariate regression coeffi-
cient, along with their associated standard errors, were
averaged from replicates. The results were expressed as
odds-ratios (OR) with 95% confidence intervals (95%CI).
To illustrate these results, a receiver operating characteris-
tic (ROC) analysis was proposed, with the area under the
curve (AUROC) estimated and presented with 95%CI.
Results
From January 2014 to December 2015, of over 993 pa-
tients taking antiplatelet drugs, 293 (29.5%) patients pre-
senting with TBI and CT scans were included (Fig. 1).
Of these, CT scan revealed no intracranial bleeding in
267 (91.1%) (CT group-), versus bleeding in 26 (8.9%)
(CT group+). Overall, 262 (89.4%) were injured by falls,
22 (7.5%) by road accidents, two (0.7%) by assaults, and
seven (2.4%) by other causes.
Mean age, patient > 75 years, and female-male rate
were similar between the CT group- and CT group+
(Table 1). However, patients in the CT group+ were
more likely to have major bleeding history and concomi-
tant therapy with ASA and clopidrel than those in the
CT group- (15% vs. 3 and 19% vs. 6%, respectively). Fol-
lowing their TBI, those in the CT group+ were more
likely to present with loss of consciousness or amnesia
and headaches or vomiting than those in the CT group-
(73% vs. 38.5, 34.6% vs. 9.7%, respectively). Moreover, on
arrival, CT group+ patients exhibited lower median
Glasgow Coma scales than the CT group- (14 vs.15).
Among the 26 patients in CT group+, the Rotterdam
CT-score was 1 for 10 patients (38.5%), 2 for 10 (38.5%),
3 for three (11.5%), and 4 for three (11.5%). Thirteen
Fig. 1 Flowchart. Abbreviations: DOACs: direct oral anticoagulants; VKA: vitamin K antagonist; CT: computed tomography
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patients had only one cerebral bleeding and the other 13
had multiple cranial bleeding. The CT scan found 16
(61.5%) subdural hematoma, 13 (50%) subarachnoid
hemorrhage, 10 (38.5%) intraparenchymal hematoma
and 0 extradural hematoma. Moreover, six patients
(23.1%) underwent surgery (1 decompressive craniect-
omy, 1 external ventricular drainage and 4 drainage) and
five (19.2%) died during hospitalization (median: 2.5 days,
interquartile range [IQR] [1–11]:), despite two undergo-
ing neurosurgery.
On multivariable analysis, patients with history of
major bleeding (OR: 8.47; 95%CI: 1.56–45.82) receiving
concomitant therapy with ASA and clopidogrel (OR:
6.46; 95%CI: 1.46–28.44), and presenting with headache
or vomiting on arrival (OR: 4.27; 95%CI: 1.44–12.60), or
abnormal Glasgow coma scale (OR: 8.60; 95%CI: 2.85–
25.99) were at increased risk of intracranial bleeding fol-
lowing TBI if taking antiplatelets (Table 2).
The AUROC obtained from this multivariable analysis
was high: 0.85 (95%CI 0.77–0.93). The Receiver Operat-
ing Characteristic (ROC) curve is shown in Fig. 2.
Discussion
Our study reported on a large series of consecutive pa-
tients with TBI taking antiplatelet agents only, revealing
that one in every 10 patients had intracranial bleeding.
This result is consistent with reports of previous studies
[24, 36, 37]. We found that four variables, easily avail-
able at baseline, may help clinicians identify patients
with increased risk of intracranial bleeding: history of
major bleeding, concomitant ASA with clopidogrel treat-
ment, Glasgow coma scale, and headache or vomiting.
Interestingly, the absence of all four of these factors on
admission constitutes a predictive model with an area
under the curve of 0.85 (95%CI: 0.77–0.93) to avoid
intracranial bleeding.
Unexpectedly, after multivariable analysis, our study
revealed that neither age nor loss of consciousness were
predictive of intracranial bleeding. Age is a well-known
bleeding risk factor, used in many bleeding risk scores
[25, 28, 38, 39]. Nevertheless, our study along with
others have demonstrated that old age, independent of
signs and symptoms, is not considered an a priori risk
factor for intracranial lesions, with 89% of our patients
being over 65 years old [9, 40]. Previous studies sug-
gested that patients who sustain minor head injuries
are more likely to suffer intracranial bleeding if they
have a history of loss of consciousness [13, 41]. How-
ever, as loss of consciousness was a subjective risk
factor, other studies did not associate it with intracra-
nial bleeding [42–45].
French guidelines recommend a CT scan 4 to 8 h fol-
lowing TBI in patients taking antiplatelet agents,
whereas others do not constitute antiplatelet use as a
Table 1 Characteristics of patients with traumatic brain injury
according to presence or not of intracranial bleeding on CT
scan
CT group - CT group + p-value
Patient, N 267 26
Sex
Women, n (%) 145 (54%) 11 (52%) 0.24
Age, mean +/− sd 80+/−11.1 80+/−10.5 0.98
> 65 years, n (%) 237 (88%) 24 (92%) 0.75
> 75 years, n (%) 209 (78%) 19 (73%) 0.54
Medical history, n (%)
Stroke 61 (22%) 8 (32%) 0.30
Cancer 36 (13%) 4 (15%) 0.76
Major bleeding 9 (3%) 4 (15%) 0.02
Risk of falling 149 (55%) 19 (73%) 0.10
Renal or hepatic failure 69 (25%) 5 (19%) 0.45
Hypertension 158 (63%) 18 (75%) 0.24
Antiplatelet, n (%)
ASA alone 199 (74.5%) 17 (65.4%) 0.31
Clopidogrel alone 46 (17.2%) 4 (15.4%) 0.81
ASA + clopidogrel 18 (6%) 5 (19%) 0.04
ASA + anti-Gp2b3a 4 (1.5%) 0 (0%) 1
Clinical characteristics, n (%)
High-energy trauma 35 (13%) 5 (19%) 0.37
Alcohol 13 (4%) 0 (0%) 0.61
Loss of consciousness
or amnesia
103 (38.5%) 19 (73%) < 0.001
Headache or vomiting 26 (9.7%) 9 (34.6%) < 0.001
Glasgow coma scale,
median (IQR)
15 [15–15] 14 [13–15] < 0.001
Biological characteristics, n (%)
Anemia 67 (27%) 8 (30%) 0.68
Thrombocytopenia 23 (9%) 2 (8%) 1
CrCl ml/min, median (IQR) 66 [51–84] 65 [52–77] 0.72
CT computed tomography, ASA acetylsalicylic acid, CrCl creatinine clearance,
IQR interquartile range
Table 2 Multivariate analysis of patient characteristics according
to the risk of intracranial bleeding on CT scan
Odds ratio 95%CI p-value
Major bleeding 8.47 1.56–45.82 0.013
ASA + clopidogrel 6.46 1.46–28.44 0.014
Headache or vomiting 4.27 1.44–12.60 0.008
Glasgow coma scale 8.60 2.85–25.99 < 0.001
Women 1.59 0.60–4.15 0.34
Age 0.98 0.94–1.03 0.63
Loss of consciousness or amnesia 2.21 0.81–6.02 0.11
ASA acetylsalicylic acid, CI confidence interval
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risk factor of intracranial bleeding [21–23]. TBI cases with
antiplatelet agents were associated with higher mortality
compared to those without [46, 47]. The mechanism for
this appears to be the extent of intracranial bleeding in pa-
tients taking antiplatelet agents, making them more likely
to present more severe intracranial bleeding [46]. These
severe intracranial bleeding cases involving antiplatelets
were associated with 50% mortality, similar to the high
mortality rate that occurred in those receiving anticoagu-
lants [46, 48]. For patients receiving anticoagulants, bleed-
ing progression was shown to be prevented and mortality
reduced when these patients’ treatments were quickly re-
versed [49, 50]. However, for those taking antiplatelet
agents, no reverse therapy exists.
A further challenge is posed by the increasing overcrowd-
ing of EDs by patients [51, 52]. This leads to long waiting
times before a CT scan can be carried out, presenting a risk
that patients needing urgent care may not be treated in
time [53]. One recent study reported that a combination of
clinical information upon ED admission enables early and
more adequate risk stratification [54, 55]. Interestingly, to
our knowledge, this is the first real-life study to find signifi-
cant predictive factors of intracranial bleeding following
TBI with antiplatelet treatment, with half the patients thus
able to avoid CT scan.
Our study has potential limitations, however. First,
since our study is an observational study (and not a ran-
domized trial), our data is only hypothesis-generating,
potentially providing a useful basis for future controlled
clinical trials. Secondly, emergency physicians were free
to choose whether or not to perform CT scans for TBI
patients taking antiplatelet agents, and were probably
more likely to avoid CT scans for patients at low risk of
intracranial bleeding. Thirdly, the patients were recruited
in a single center, which can cause less reproducibility,
though avoids any variability of practices in different
centers. Unfortunately, patients with normal CT scan
weren’t follow after there discharged from the ward to
look at delayed intracranial hemorrhage. However, it
wasn’t recommended by French guidelines based on the
study of Af-Geijerstam et al. who showed that, in a com-
puted tomography strategy with a mean of 5.2 h after
head trauma, no patients with normal findings on the
scan had later complications (“false negatives”) [21, 56].
The main strengths of our observations were a real-life
management of TBI under antiplatelet agents and a high
number of consecutively included patients. Moreover,
Considering the model proposed in this work, our re-
sults seem powerful and robust. According to works
proposed by Tosteson et al. and Demidenko, the statis-
tical power was greater than 85% [57, 58].
Conclusion
Our study demonstrated that the absence of history of
severe hemorrhage, dual antiplatelet therapy, headache
or vomiting, or abnormal Glasgow coma scale score ap-
pears to predict a normal CT scan following TBI in pa-
tients taking antiplatelets. This finding do not apply to
patients with anticoagulants and needs to be validated
by prospective studies to avoid unnecessary CT scans
being performed in this particular population presenting
with TBI and taking antiplatelet agents admitted to EDs.
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